Department of Internal Medicine, College of Medicine, Institute of Kidney Disease Research, Yonsei University, Seoul, Republic of Korea.
Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
Am J Kidney Dis. 2021 Aug;78(2):236-245. doi: 10.1053/j.ajkd.2020.12.013. Epub 2021 Jan 11.
RATIONALE & OBJECTIVE: Optimal blood pressure (BP) control is a major therapeutic strategy in the management of chronic kidney disease (CKD). We studied the association between BP and adverse kidney outcomes within a diverse cohort of Koreans with CKD.
Prospective observational cohort study.
SETTING & PARTICIPANTS: 2,044 participants from the Korean Cohort Study for Outcomes in Patients With CKD (KNOW-CKD).
Baseline and time-updated systolic BP (SBP) and diastolic BP (DBP).
A composite kidney outcome of a≥50% decline in estimated glomerular filtration rate (eGFR) from the baseline value or incident kidney replacement therapy.
Multivariate cause-specific hazards models and marginal structural models were fitted for baseline and time-updated BP, respectively.
During 7,472 person-years of follow-up, the primary composite kidney outcome occurred in 473 participants (23.1%), an incidence rate of 63.3 per 1,000 patient-years. Compared with baseline SBP<120mm Hg, the hazard ratios (HRs) for 120-129, 130-139, and≥140mm Hg were 1.10 (95% CI, 0.83-1.44), 1.20 (95% CI, 0.93-1.59), and 1.43 (95% CI, 1.07-1.91), respectively. This association was more evident in the model with time-updated SBP, for which the corresponding HRs were 1.31 (95% CI, 0.98-1.75), 1.59 (95% CI, 1.16-2.16), and 2.29 (95% CI, 1.69-3.11), respectively. In the analyses of DBP, we observed that time-updated DBP but not baseline DBP was significantly associated with the composite kidney outcome. Compared to patients with SBP<120mm Hg, patients with higher SBP had steeper slopes of eGFR decline. In the model including both SBP and DBP, only SBP was significantly associated with the composite kidney outcome.
Observational design, unmeasured confounders, and use of office BPs only.
In patients with CKD, higher SBP and DBP levels were associated with a higher risk of a composite kidney outcome reflecting CKD progression. SBP had a greater association with adverse kidney outcomes than DBP.
血压(BP)的最佳控制是慢性肾脏病(CKD)管理中的主要治疗策略。我们研究了在一个多样化的韩国 CKD 患者队列中,BP 与不良肾脏结局之间的关系。
前瞻性观察队列研究。
来自韩国 CKD 患者结局研究(KNOW-CKD)的 2044 名参与者。
基线和时间更新的收缩压(SBP)和舒张压(DBP)。
eGFR 基线值下降≥50%或发生肾脏替代治疗的复合肾脏结局。
分别为基线和时间更新的 BP 拟合多变量特定原因风险模型和边缘结构模型。
在 7472 人年的随访期间,473 名参与者(23.1%)发生了主要复合肾脏结局,发生率为每 1000 人年 63.3 例。与基线 SBP<120mmHg 相比,SBP 为 120-129mmHg、130-139mmHg 和≥140mmHg 的危险比(HRs)分别为 1.10(95%可信区间,0.83-1.44)、1.20(95%可信区间,0.93-1.59)和 1.43(95%可信区间,1.07-1.91)。这种关联在时间更新的 SBP 模型中更为明显,相应的 HR 分别为 1.31(95%可信区间,0.98-1.75)、1.59(95%可信区间,1.16-2.16)和 2.29(95%可信区间,1.69-3.11)。在 DBP 的分析中,我们观察到时间更新的 DBP 而不是基线 DBP 与复合肾脏结局显著相关。与 SBP<120mmHg 的患者相比,SBP 较高的患者 eGFR 下降的斜率更陡峭。在包括 SBP 和 DBP 的模型中,只有 SBP 与复合肾脏结局显著相关。
观察性设计、未测量的混杂因素和仅使用办公室 BP。
在 CKD 患者中,较高的 SBP 和 DBP 水平与反映 CKD 进展的复合肾脏结局风险增加相关。SBP 与不良肾脏结局的相关性大于 DBP。